Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | KDM5A | P29375 | 1/20 | 0.31 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26067069 | 0.76 | SYK (0.44) | CYP2C9CYP2E1CYP2A6CYP2B6CYP2C19 | |
| SCHEMBL26671415 | 0.73 | ALDH1A1 (0.39) | CYP2C9CYP2E1CYP2A6CYP2B6CYP2C19 | |
| SCHEMBL31595730 | 0.73 | KMT2A (0.39) | CYP2C9KDM5BKDM4ECYP1A2CYP3A4 | |
| SCHEMBL31596016 | 0.73 | BAZ2B (0.32) | CYP1A2CYP3A4 | |
| SCHEMBL31595885 | 0.70 | COMT (0.36) | MAPT | |
| SCHEMBL31597158 | 0.69 | CYP2E1 (0.33) | CYP2C9CYP2E1CYP2A6CYP2B6CYP2C19 | |
| SCHEMBL26778138 | 0.69 | HDAC6 (0.33) | CYP2C9CYP2E1CYP2A6CYP2B6CYP2C19 | |
| SCHEMBL31595956 | 0.68 | CCR1 (0.47) | CYP2C9CYP2A6CYP2C19KDM4ECYP1A2 | |
| SCHEMBL31595762 | 0.66 | CYP2C19 (0.40) | CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL31597272 | 0.66 | COMT (0.39) | CYP2C9CYP2C19KDM4ECYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171437-A1 | (4-BENZO[D]OXAZOL-2-YL)-6,7-DIHYDRO-1H-IMIDAZO[4,5-C]PYRIDINE-5(4H)-YL)METHANONE DERIVATIVES AS MUTANT PAH STABILIZERS FOR THE TREATMENT OF PHENYLKETONURIA | AGIOS PHARMACEUTICALS, INC. | 2025-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171437-A1 | (4-BENZO[D]OXAZOL-2-YL)-6,7-DIHYDRO-1H-IMIDAZO[4,5-C]PYRIDINE-5(4H)-YL)METHANONE DERIVATIVES AS MUTANT PAH STABILIZERS FOR THE TREATMENT OF PHENYLKETONURIA | PAH, BCKDK, PKM | CYP2C9 597/4885CYP2E1 1298/4885CYP2A6 427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.